Evaluation of a Novel Signature for PARP Inhibitor Sensitivity Prediction
Evaluation of a novel signature for PARP inhibitor sensitivity prediction using real-world data. Evaluation of a novel PARP inhibitor sensitivity biomarker using real-world data. First Author: Emily Vucic, Zephyr AI Background Tumors with homologous recombination repair deficiencies (HRD+) are susceptible to PARP inhibitors (PARPi) which exploit a synthetic lethality by targeting an essential base excision … Read more